In recent years, the adalimumab biosimilar market has gained substantial momentum, projected to grow at an impressive CAGR of approximately 17.60% from 2024 to 2032. This surge is primarily attributed to the rising incidence of rheumatoid arthritis, particularly among the rapidly expanding geriatric population. With healthcare systems seeking cost-effective treatments, the demand for biosimilars has … Read more
Disclaimer:
We do not claim ownership of any content, links or images featured on this post unless explicitly stated. If you believe any content or images infringes on your copyright, please contact us immediately for removal (info@frobyn.com). Please note that content published under our account may be sponsored or contributed by guest authors. We assume no responsibility for the accuracy or originality of such content. We hold no responsibility for content and images published as ours is a publishers platform. Mail us for any query and we will remove that content/image immediately.